rs1800547 — MAPT H1/H2 Haplotype Splice Regulator

Intronic MAPT variant that regulates tau exon 3 splicing via hnRNP F/Q binding, distinguishing H1 (risk) from H2 (protective) haplotypes for Parkinson's disease, PSP, corticobasal degeneration, and Alzheimer's disease

See your personal result for MAPT

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MAPT rs1800547 — The Molecular Switch in Tau's H1/H2 Divide

Within the microtubule-associated protein tau (MAPT) gene on chromosome 17q21, a single nucleotide difference at rs1800547 marks one of the most consequential forks in human neurological risk: the ancient H1/H2 haplotype boundary. While the broader H1/H2 distinction spans a 900-kilobase chromosomal inversion, rs1800547 is the canonical SNP that directly differentiates the H1 and H2 clades11 canonical SNP that directly differentiates the H1 and H2 clades
The GenePD Study found rs1800547 was the single most statistically significant variant in the region for Parkinson's disease after multiple testing correction. Unlike rs17649553, which is another H1/H2 tag in the region, rs1800547 has been shown to have direct molecular function — not merely a passive marker of haplotype membership.

The MAPT gene produces tau, a protein whose primary job is stabilizing the neuronal microtubule skeleton and supporting axonal transport. When tau becomes hyperphosphorylated and misfolds, it aggregates into neurofibrillary tangles, the pathological hallmark of tauopathies including Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

The Mechanism: Splice Factor Binding and Exon 3

A landmark 2017 study using whole-locus MAPT expression vectors demonstrated that rs1800547, working together with rs17651213, directly controls haplotype-specific inclusion of MAPT exon 322 A landmark 2017 study using whole-locus MAPT expression vectors demonstrated that rs1800547, working together with rs17651213, directly controls haplotype-specific inclusion of MAPT exon 3
Exon 3 encodes a region of the N-terminal projection domain of tau that affects its interaction with membranes and the neuronal cytoskeleton. Using electrophoretic mobility shift assays, researchers found that the H1 (A) and H2 (G) alleles at rs1800547 create distinct RNA-protein binding patterns with splicing factors hnRNP F and hnRNP Q — critical regulators of alternative splicing in neurons. The H2 sequence at this position allows 1.76-fold higher exon 3 inclusion compared to H1, altering the proportion of N1 and N2 tau isoforms.

This matters because the balance of tau isoforms — not just total tau levels — appears critical to which tauopathy, if any, develops. H1 is associated with elevated 4-repeat (4R) tau isoforms, which are the primary constituents of pathological aggregates in PSP and CBD. H2's different splicing pattern may shift the balance away from aggregation-prone 4R isoforms.

The Evidence for Parkinson's Disease

The GenePD Study genotyped 21 SNPs across the MAPT region in PD families and controls, finding that rs1800547 emerged as the most statistically significant variant for PD association, surviving multiple testing correction33 The GenePD Study genotyped 21 SNPs across the MAPT region in PD families and controls, finding that rs1800547 emerged as the most statistically significant variant for PD association, surviving multiple testing correction
The study also found 4-repeat MAPT isoforms significantly elevated in PD brains (p=0.002), linking the H1 splicing signature to disease pathology. A large case-control study of 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for PD compared to H1/H2 and H2/H2 carriers44 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for PD compared to H1/H2 and H2/H2 carriers
The association held across familial and sporadic disease, both sexes, and early- and late-onset subgroups.

Progressive Supranuclear Palsy: The Strongest Association

The H1/H1 genotype is found in approximately 94% of PSP patients compared to ~64% of the general population — a striking enrichment. A JAMA Neurology study of 802 neuropathologically confirmed PSP cases identified H1 subhaplotypes with markedly elevated risk: H1d (OR 1.86), H1g (OR 3.64), and H1o (OR 2.60)55 802 neuropathologically confirmed PSP cases identified H1 subhaplotypes with markedly elevated risk: H1d (OR 1.86), H1g (OR 3.64), and H1o (OR 2.60)
These sub-haplotype associations suggest that specific combinations of H1-background variants, on top of the rs1800547 A allele, determine the magnitude of PSP risk. The chromosome 17q21.31 region — anchored by rs1800547 — represents the single strongest genetic risk locus for PSP identified to date.

Alzheimer's Disease: A Different Pathway

A study of 17,996 participants (8,559 AD cases, 9,437 controls) across Spanish and international cohorts found that rs1800547 itself was associated with AD risk (OR 1.12, p=0.0025)66 A study of 17,996 participants (8,559 AD cases, 9,437 controls) across Spanish and international cohorts found that rs1800547 itself was associated with AD risk (OR 1.12, p=0.0025)
The effect was strongest in APOE ε4 non-carriers — suggesting MAPT H1 represents an alternative causal pathway to AD distinct from amyloid-driven disease. The risk was highest in individuals over age 77 without APOE ε4 (p=0.001), suggesting a late-life tau-driven pathway independent of beta-amyloid accumulation. For people without the APOE ε4 allele, the MAPT H1 haplotype tagged by rs1800547 becomes a more prominent contributor to AD risk.

ALS and Frontotemporal Spectrum

Beyond the primary tauopathies, a 2023 study of Bulgarian ALS patients found the H1b subhaplotype (containing the rs1800547 A allele) conferred a nearly 2-fold increased risk for sporadic ALS77 a 2023 study of Bulgarian ALS patients found the H1b subhaplotype (containing the rs1800547 A allele) conferred a nearly 2-fold increased risk for sporadic ALS
The authors propose that fine transcriptional regulation at the MAPT locus, including rs1800547's splice factor interactions, may influence ALS susceptibility through shared tau biology with FTD. ALS and FTD share genetic and pathological overlap, and MAPT variation may contribute to the clinical spectrum between them.

Practical Actions

For H1/H1 carriers (AA genotype), the relevant clinical considerations are monitoring for motor symptoms that might indicate early parkinsonism, PSP, or CBD — conditions where early specialist evaluation matters for accurate diagnosis and prognosis. PSP in particular is frequently misdiagnosed as Parkinson's disease but responds differently to treatment. For the Alzheimer's disease risk — especially relevant for APOE ε4 non-carriers — knowing your MAPT status can help contextualize the late-life cognitive monitoring picture.

There are currently no approved pharmacological agents specifically targeting MAPT splicing or H1-driven tau isoform imbalance, though several anti-tau therapies are in clinical trials. Lifestyle factors — particularly aerobic exercise and head trauma prevention — have independent evidence for neuroprotection across multiple pathways relevant to tauopathy risk.

Interactions

rs1800547 and rs17649553 both tag the same H1/H2 haplotype and are in very strong linkage disequilibrium. If a person's genome contains both SNPs, their results should be concordant. The H1 risk at this locus compounds with rs356182 (SNCA) for Parkinson's disease risk — though interaction analyses have found these act independently rather than epistatically. In Alzheimer's disease, the H1/H2 distinction interacts with APOE genotype (rs429358), with H1 risk most pronounced in APOE ε4 non-carriers.

Genotype Interpretations

What each possible genotype means for this variant.

AG H1/H2 Heterozygote Intermediate

One copy each of H1 and H2 — intermediate tauopathy risk, partial H2 protection

With one A (H1) and one G (H2) allele, your cells produce tau isoforms from both haplotype backgrounds. The H2-driven exon 3 splicing contributes higher exon 3 inclusion in a proportion of transcripts, partially shifting the 4R:3R tau balance compared to H1/H1. This molecular heterozygosity appears to translate into intermediate disease risk.

For PSP — the most strongly H1-associated disease — the H1/H2 genotype is found in roughly the expected population proportion in case series, suggesting limited but not absent protection. For Parkinson's disease, meta-analyses estimate a risk reduction of roughly half the H1/H1 effect compared to H2/H2.

For Alzheimer's disease in APOE ε4 non-carriers, your risk trajectory falls between the two homozygous genotypes. The H2 allele may partially buffer the H1-driven tau isoform imbalance, though complete protection requires H2/H2 status.

AA H1/H1 Homozygote High Risk

Two copies of the H1 haplotype — elevated risk for Parkinson's, PSP, CBD, and Alzheimer's disease

The molecular basis for H1/H1 risk lies in altered splicing of MAPT exon 3. The A allele at rs1800547 creates different RNA-protein complex binding patterns for splice factors hnRNP F and hnRNP Q compared to the G allele. This shifts tau isoform production toward 4-repeat (4R) tau, which is the predominant form found in pathological aggregates in PSP, corticobasal degeneration, and some forms of Parkinson's disease.

Within the broader H1 haplotype, sub-haplotypes carry different magnitudes of risk. H1g (OR 3.64 for PSP) and H1o (OR 2.60) represent high-risk H1 configurations, while other H1 sub-haplotypes carry more moderate risk. The rs1800547 A allele is necessary but not sufficient for these diseases — environmental, lifestyle, and other genetic factors also shape whether H1/H1 individuals develop tauopathy.

For the Alzheimer's disease association: a combined analysis of nearly 18,000 participants found rs1800547 explicitly associated with AD risk at p=0.0025, with the effect strongest in APOE ε4 non-carriers over age 77. This suggests H1 represents an alternative, slower causal pathway to AD that is less dependent on amyloid burden than the APOE pathway. Screening and monitoring approaches for AD may need to be individualized based on which pathways are most active.

GG H2/H2 Homozygote Decreased

Two copies of the protective H2 haplotype — substantially reduced risk for most tauopathies

The H2 haplotype's protective effect appears mechanistically linked to its distinct exon 3 splicing pattern. H2 sequences at rs1800547 support 1.76-fold higher exon 3 inclusion compared to H1, producing a tau isoform balance that is less prone to forming the 4R-rich aggregates characteristic of PSP and CBD.

Despite protection against the most common tauopathies, H2/H2 status is associated with increased risk for Pick's disease — a 3-repeat (3R) tauopathy. This inverse relationship supports the hypothesis that the H1/H2 polymorphism controls the 3R:4R tau ratio through exon 10 and exon 3 splicing regulation. H2-driven higher 3R tau may increase susceptibility to 3R-predominant tauopathies like Pick's disease, while protecting against 4R tauopathies.

The rarity of H2 outside European populations (found at ~20% allele frequency in Europeans but <2% in East Asians and Africans) suggests possible positive selection in European ancestral populations, perhaps related to differential neurodegeneration risk profiles or other pleiotropic effects.